Literature DB >> 1551938

Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism.

H M Chapel1, M Lee.   

Abstract

Fifteen patients with low-grade B-cell tumours were given 3-weekly infusions for 1 year of intravenous immunoglobulin (IVIg) at a dose of 0.4 g/kg. Serial measurements of serum IgG levels were made; analysis of eight samples taken at intervals after the end of the last (17th) infusion showed that the half-life of IgG in such patients was no shorter than in normal individuals. To look at the average rates of catabolism of IgG during the year serum IgG was measured at four time points (pre, post, day 7, and day 21) after the 5th, 8th, 13th, and 17th infusions; these data showed that there were no changes in catabolism. Finally, there was a significant correlation (P less than 0.005) between the pretreatment serum IgG level and the increase to the mean trough level achieved after the fifth and subsequent infusions (in each individual). These data suggest that the catabolic rate of IgG is normal in patients with low-grade B-cell tumours and that it is not altered by regular IVIg infusions once a steady state is reached. Significant correlation of the increment of serum IgG with the endogenous synthesis level supports the theory that the IgG half-life is proportional to the IgG level at any given time.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551938     DOI: 10.1007/bf00918268

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  7 in total

1.  A two-phase linear regression model for biologic half-life data.

Authors:  M L Lee; W Y Poon; H S Kingdon
Journal:  J Lab Clin Med       Date:  1990-06

2.  Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial.

Authors:  Robert Peter Gale; Helen M Chapel; Christopher Bunch; Kanti R Rai; Kenneth Foon; Suzanne G Courter; Dierdre Tait
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

Review 3.  Down regulation of Fc receptors by IVIgG.

Authors:  J W Mannhalter; M M Eibl
Journal:  Int Rev Immunol       Date:  1989       Impact factor: 5.311

4.  Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors.

Authors:  H Griffiths; V Brennan; J Lea; C Bunch; M Lee; H Chapel
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

Review 5.  Metabolism of immunoglobulins.

Authors:  T A Waldmann; W Strober
Journal:  Prog Allergy       Date:  1969

6.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.

Authors:  S Mankarious; M Lee; S Fischer; K H Pyun; H D Ochs; V A Oxelius; R J Wedgwood
Journal:  J Lab Clin Med       Date:  1988-11

7.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

  7 in total
  5 in total

1.  Chronic lymphocytic leukaemia at a county hospital in southern Sweden.

Authors:  V Hjalmar; M Carlsson; E Kimby
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

Review 2.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

3.  Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency.

Authors:  J Waniewski; A Gardulf; L Hammarström
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

4.  Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice.

Authors:  Qian Xu; Zaiping Zhang; Zhiming Chen; Biying Zhang; Chanyuan Zhao; Yimin Zhang; Conghui Zhao; Xiaodong Deng; Yao Zhou; Yanyun Wu; Jiang Gu
Journal:  Cancer Manag Res       Date:  2019-03-07       Impact factor: 3.989

5.  Misleading Positive Serology for Cat Scratch Disease following Administration of Intravenous Immunoglobulin.

Authors:  Michal Yakubovsky; Yoav Golan; Alex Guri; Itzhak Levy; Daniel Glikman; Moshe Ephros; Michael Giladi
Journal:  Pathogens       Date:  2022-01-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.